Abstract

There is consistent evidence that many of the pregnancy complications that occur late in the second and third trimester can be predicted from an integrated 11–13 weeks visit, where a maternal and fetal assessment are comprehensively performed. The traditional aims of the 11–13 weeks visit have been: establishing fetal viability, chorionicity and dating of the pregnancy, and performing the combined screening test for common chromosomal abnormalities. Recent studies have shown that the first trimester provides important information that may help to predict pregnancy complications, such as preeclampsia and fetal growth restriction, stillbirth, preterm birth, gestational diabetes mellitus and placenta accreta spectrum disorder. The aim of this manuscript is to review the methods available to identify pregnancies at risk for adverse outcomes after screening at 11–13 weeks. Effective screening in the first trimester improves pregnancy outcomes by allowing specific interventions such as administering aspirin and directing patients to specialist clinics for regular monitoring.

Highlights

  • Received: 25 January 2022The early assessment of patient specific risks of pregnancy complications has the purpose to improve pregnancy outcome and to individualize the patient- and diseasespecific approach

  • Low-risk pregnancy includes a low chance for a chromosomal abnormalities ratio after the first trimester combined screening test, that includes maternal history, fetal ultrasound assessment and serum biochemistry assessment of beta-hCG and PAPP-A, and a low chance of maternal pregnancy complications considered after assessing the chance for developing preeclampsia, fetal growth restriction and preterm delivery, by using maternal history characteristics, ultrasound aspects and the serum biochemistry of PAPP-A, soluble fms-like tyrosine kinase 1, and placental growth factor (PlGF) [1]

  • First trimester screening by a combination of maternal characteristics and obstetrical history, with the measurement of cervical length, can predict more than 50% of preterm births before 34 weeks’ gestation

Read more

Summary

Introduction

The early assessment of patient specific risks of pregnancy complications has the purpose to improve pregnancy outcome and to individualize the patient- and diseasespecific approach. Low-risk pregnancy includes a low chance for a chromosomal abnormalities ratio after the first trimester combined screening test, that includes maternal history, fetal ultrasound assessment and serum biochemistry assessment of beta-hCG (beta human chorionic gonadotropin) and PAPP-A (pregnancy-associated plasma protein-A), and a low chance of maternal pregnancy complications considered after assessing the chance for developing preeclampsia, fetal growth restriction and preterm delivery, by using maternal history characteristics, ultrasound aspects and the serum biochemistry of PAPP-A, soluble fms-like tyrosine kinase 1 (sFlt-1), and placental growth factor (PlGF) [1] The aim of this manuscript is to review the methods available to identify pregnancies at risk for adverse outcomes after screening at 11–13 weeks.

Detection of Chromosomal Abnormalities and Fetal Structural Defects
Screening for Preeclampsia
Screening for Preterm Birth
Screening for Stillbirth
Screening for Gestational Diabetes Mellitus
Screening for Placenta Accreta Spectrum Disorders
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call